Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Methenolone (also spelled metenolone) is a synthetic anabolic-androgenic steroid (AAS) derived from dihydrotestosterone (DHT). It is best known by the trade name Primobolan (oral acetate form) and Primobolan Depot (injectable enanthate form), originally developed by Schering AG in West Germany in 1961. Historically used clinically for the treatment of severe anemia from bone marrow failure and for muscle wasting conditions, methenolone is no longer manufactured by major pharmaceutical companies for human use in most jurisdictions.
Methenolone has a notable reputation in non-medical contexts as a "mild" or "side-effect-friendly" compound. This reputation is partially deserved but frequently overstated, and the gap between perception and reality is itself a harm-reduction concern worth addressing directly.
Once cleaved from the ester, the methenolone molecule has a short circulating half-life of several hours. The ester (or the 1-methyl modification, in the oral acetate form) is what allows therapeutic dosing schedules.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Acetate (oral) | ~5 hours |
| Enanthate (injectable) | ~10.5 days |
What it does
Main effects
- Modest anabolic activity: lower AR binding affinity than testosterone, DHT, or trenbolone; clinically described as a low-to-moderate potency anabolic
- No aromatization to estrogen: does not produce water retention, gynecomastia, or other estrogen-mediated effects from itself
- Oral bioavailability without 17α-alkylation: the 1-methyl modification provides oral activity through a non-hepatotoxic pathway, a property nearly unique among orally bioavailable AAS
- Stimulation of erythropoiesis: the basis of the original therapeutic indication for aplastic anemia
- Generally favorable lipid impact compared to other non-aromatizing oral compounds (still negative, just less so)
- Preserves muscle without estrogenic water retention, the basis of its non-medical reputation as a "cutting" compound
What to watch for
Common side effects
- HPG axis suppression: meaningful suppression of endogenous testosterone, LH, and FSH; the "doesn't suppress" claim is overstated
- HDL cholesterol reduction and modest LDL elevation: less pronounced than with more potent non-aromatizing compounds, but clinically meaningful with prolonged use
- Erythrocytosis: moderate hematocrit elevations are common; less pronounced than with testosterone or trenbolone at equivalent doses
- Accelerated scalp hair loss in genetically predisposed users: DHT-derived; 5α-reductase inhibitors do not directly mitigate this effect
- Acne and androgenic skin effects: generally milder than more potent AAS but still present
- Virilization in women: voice deepening, clitoral enlargement, and other androgenic effects can occur and are often partially or fully irreversible; the "mild" reputation underestimates this risk
- Cumulative hepatic effects with long-duration oral use: the "non-hepatotoxic oral" framing is partially true but encourages extended cycles that may produce cumulative liver effects
- Counterfeit product risk: methenolone is among the most counterfeited AAS in the unregulated market; users frequently receive products that contain other compounds or are entirely inert
Key facts
Key facts worth knowing
- Methenolone cannot aromatize to estrogen due to its structure as a 5α-reduced DHT derivative. It does not raise estradiol, does not cause estrogen-mediated water retention, and does not cause estrogen-mediated gynecomastia.
- Despite being orally bioavailable, methenolone acetate is not 17α-alkylated: the unusual mechanism of oral bioavailability comes from a 1-methyl group rather than the C17α modification used by most oral steroids. This is the basis of the common claim that "Primobolan is the only oral steroid that isn't liver-toxic." This claim has substantial truth to it but is oversimplified. See the hepatic section below.
- The "mild" reputation is genuine in the sense that methenolone produces relatively few estrogenic side effects and has a relatively favorable safety profile compared to compounds like trenbolone or oxymetholone. However, it still produces suppression of endogenous testosterone production, lipid profile deterioration, erythrocytosis, and all the androgenic effects (acne, hair loss, virilization) common to AAS as a class.
- Primobolan is one of the most counterfeited compounds in the unregulated market. Independent product testing has repeatedly found products labeled as Primobolan to contain other compounds entirely, contain incorrect concentrations, or be entirely inert. This is partly because of its premium price and partly because of its "safe" reputation. Counterfeiters profit by substituting cheaper compounds.
Legal status
Legal status
Schedule III controlled substance in the United States (DEA). Discontinued from FDA-approved manufacturing. WADA-prohibited at all times in competitive sport.